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Introduction
============

BCG vaccine has been the subject of numerous efficacy trials and epidemiological studies conducted over several decades. These trials indicate that BCG has 60-80% protective efficacy against severe forms of tuberculosis in children, particularly meningitis,[@ref1] [@ref2] and its efficacy against pulmonary diseases varies geographically.[@ref3] [@ref4] [@ref5] BCG does not seem to protect against disease when it is given to people already infected or sensitised to environmental mycobacteria, which could explain the geographical variation.[@ref6] [@ref7] [@ref8] Until recently it was not possible to establish whether the protective effect of BCG vaccination against disease was from its action in preventing acquisition of infection or limited to prevention of progression from infection to clinical disease.

The scarcity of evidence on whether the vaccine is effective against *Mycobacterium tuberculosis* infection was because of limitations of the tuberculin skin test. This test cannot distinguish a positive response caused by *M tuberculosis* infection from that caused by BCG vaccination or non-tuberculous mycobacterial infection.[@ref9] The recently developed T cell based interferon γ release assays (IGRA) can detect *M tuberculosis* infection and discriminate this from previous BCG vaccination and most non-tuberculous mycobacterial infections,[@ref10] allowing investigation of whether BCG protects against *M tuberculosis* infection.[@ref11] [@ref12] [@ref13] If BCG is found to protect against infection, it will have key implications for its use in current immunisation programmes[@ref14] as well as in the future development of new improved tuberculosis vaccines.

In this systematic review we examined the evidence for the protective effect of BCG against *M tuberculosis* infection, as opposed to against disease, in settings where children can be presumed to have been exposed to *M tuberculosis*. This therefore assesses the degree to which BCG vaccination before exposure is associated with a subsequent negative result on an interferon γ release assay. We also looked at factors that could alter the measured protective effect of BCG: latitude, the recommended age of vaccination in the area where the study was conducted, type of assay, and study quality. When there was sufficient information, we determined protection against early progression from infection to disease during screening.

Methods
=======

Search and Data Extraction
--------------------------

We searched Embase (1980 until November 2013), Medline (1950 until November 2013), and the Cochrane Library as well as reference lists of retrieved articles and conference abstracts. The search strategy was not restricted by language or year. We used the following search terms, adapted for each database when appropriate: BCG, Bacillus Calmette Guerin, tuberculosis, TB, interferon γ release assay, IGRA, ELI Spot, T-Spot TB, and QuantiFERON. We also reviewed the personal libraries of the research team. Two reviewers (AR and ME) independently screened the titles and abstracts (when available) from the search results and identified studies for assessment of full text. Disagreements were resolved by asking the opinion of a third reviewer (IA) for resolution until consensus was reached at each stage of the screening process.

Information extracted onto pretested data forms included study details (authors, year, geographical area, study design, sample size), the population (mean age, sex, and setting), exposure (method of assessment and timing), and two outcomes measures: interferon γ release assays (as a proxy for tuberculosis infection) and active tuberculosis (when reported). When relevant information was missing, we contacted study authors by email. For some studies, the stated primary outcome was not *M tuberculosis* infection but data on results of interferon γ release assays had been collected. For these studies, we contacted the authors to obtain the raw data.

Inclusion and exclusion criteria
--------------------------------

Studies meeting the following criteria were included:

-   Participants had known recent exposure to people with pulmonary tuberculosis. We assumed that in such studies, a reduced rate of infection in vaccinated versus unvaccinated children could be attributed to protection by vaccination rather than lack of exposure.

-   Participants were children aged under 16, including those who had and had not been vaccinated with BCG.

-   All children were screened for infection with *M tuberculosis* with interferon γ release assays; either in tube γ interferon quantification (QuantiFERON) or enumeration of γ interferon releasing T cells (ELISpot).

-   We excluded all studies in which interferon γ release assays was used only in children with positive results from tuberculin skin test or in which participants were not tested by interferon γ release assays or when the study reported on active tuberculosis or results of tuberculin skin test only or where the study was conducted in animals.

Quality assessment for individual studies
-----------------------------------------

Two reviewers (AR and ME) assessed aspects of the quality of each selected study using a modified version of the Newcastle-Ottawa scale for assessment of observational cohort studies.[@ref15] This scale awards a maximum of nine points to each study: four points for the adequate selection of participants, two points for comparability of the studies based on the design and analysis, and three points for the adequate ascertainment of outcome. We defined studies of high quality as those that scored ≥66.6%, moderate for 33.3-66.6%, and low for those \<33.3%. Discrepancy in quality assessment was discussed and resolved by the two reviewers.

Definitions
-----------

-   *Exposure*to tuberculosis was defined as close contact with people with active pulmonary tuberculosis as identified by the treating physicians.

-   *Infection* was defined as any positive results of interferon γ release assays in contacts irrespective of whether they had evidence of active tuberculosis or not. Participants with an indeterminate status were excluded from the analysis.

-   *Disease*was defined as presence of active tuberculosis (according to the authors) with or without a positive result on interferon γ release assays. Outcomes of both infection and active disease were identified at the point of screening for infection after exposure. A small number of additional cases might have been included as some outbreak investigations were undertaken over a period of several weeks.

Synthesis of results
--------------------

### Primary analysis---protection against infection

Our primary analysis focused on whether BCG vaccination administered before exposure was associated with a subsequent negative result on interferon γ release assay in children who had contact with infectious tuberculosis. We used binary data to categorise participants into those who were or were not vaccinated with BCG and those who did or did not have a negative assay result (independent of progression to disease), with continuity corrections applied to zero cells.[@ref16] To include all studies in a single analysis, we combined results from studies reporting both QuantiFERON and ELIspot. Where results of both assays were available from a study we chose the QuantiFERON result as this was most used among the selected studies.

### Subgroup analyses of protection against infection

We used subgroup analysis to assess whether the use of different types of interferon γ release assay (ELISpot and QuantiFERON) led to different results. We also investigated the relation between the observed effect of BCG and age at which BCG vaccination was recommended in the area where the study was conducted (we used policy recommendations because we did not have timing of BCG vaccination in individuals); geographical latitude where the study was conducted: latitudes of the study location was categorised into three groups: 0-20°, 20-40°, and \>40°; and study quality: we investigated the effect of study quality by application of the Newcastle-Ottawa scale.[@ref15] Using this scale, we compared studies with a point rating on this scale equal or above and below the median of 5 points.

### Secondary analysis---protection against infection protection against disease

In a secondary analysis, we estimated protection by BCG against active disease in a subset of six studies that reported development of active tuberculosis during screening. This was achieved by examining, in this subset, the number of children with active disease (regardless of assay status) in those who received BCG versus those who did not*.*In the population with tuberculosis infection determined from positive result on interferon γ release assays, we also examined the effect of BCG on progression from infection to early active disease by comparing the number with active disease in those who received BCG versus those who did not.

Statistical analysis
--------------------

Analysis was performed with the DerSimonian and Laird random effects model, which incorporates variation between studies in the weighting. To quantify inconsistency across studies by describing percentage of the variability in effect estimates from heterogeneity we used the I^2^ statistic with I^2^ \>40% representing moderate, \>60% substantial, and \>80% considerable heterogeneity.[@ref17] We applied a continuity correction to zero cells to include all studies in the analysis; the approach used is designed to minimise bias,[@ref16] although in our case the potential bias from any such correction would be extremely small as only one study contained zero counts and there were plenty of well powered studies. We assessed potential factors behind the heterogeneity with random effects meta-regression.[@ref18] The protective effect of BCG was described with risk ratios and 95% confidence intervals. To assess potential publication bias we used funnel plots and the Harbord test.[@ref19]

Results
=======

Study selection
---------------

Our literature search found 601 articles; based on a review of titles, we selected 546 abstracts for further assessment leading to the identification of 133 articles for full text review (fig 1).[](#fig1){ref-type="fig"} After we reviewed the full text, 112 articles did not meet the inclusion criteria. The 21 remaining articles (describing 21 studies) were selected for potential inclusion. Fourteen articles stated that interferon γ release assays were carried out but did not report the results on the relation between BCG vaccination and assay. The authors were contacted and asked to provide the raw data. For seven such studies, we received no response after repeated attempts. The analysis therefore included 14 studies (fig 1).[](#fig1){ref-type="fig"}

![**Fig 1** Study selection for systematic review of BCG vaccination against mycobacterium tuberculosis infection in children](roya016946.f1_default){#fig1}

Characteristics of included studies
-----------------------------------

The meta-analysis included cohort studies of children who were screened as part of an investigation of a tuberculosis outbreak,[@ref11] [@ref12] [@ref20] [@ref21] [@ref22] who were referred to hospital as close contacts of index cases,[@ref20] [@ref21] [@ref23] [@ref24] [@ref25] were household contacts of an infectious adult,[@ref13] [@ref26] [@ref27] [@ref28] or were contacts in other settings.[@ref29] Four studies were conducted in the United Kingdom, two each in the Gambia and Spain, and a single study in Greece, Italy, Indonesia, Turkey, South Africa, and Cambodia each (table).[](#tbl1){ref-type="table"} BCG vaccination status was assessed in included studies by one or a combination of BCG scar,[@ref12] [@ref13] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref29] [@ref30] confirmed medical records,[@ref11] [@ref12] [@ref21] [@ref30] and parental recall of vaccination.[@ref21]

###### 

Characteristics of studies included in systematic review of effect of BCG vaccination against mycobacterium tuberculosis infection in children

                     Study period                   Country        Setting                                                                         No of participants   Age group (years)   Quality rating\*
  ------------------ ------------------------------ -------------- ------------------------------------------------------------------------------- -------------------- ------------------- ------------------
  Adetifa 2010       NS                             Gambia         Childhood household contacts                                                    236†                 6 months-14         Moderate
  Altet-Gomez 2011   Sept 2005-Sept 2007            Spain          Contacts with smear positive active TB patient                                  166                  \<15                Moderate
  Bianchi 2009       1 July 2005-31 December 2006   Italy          Referred to hospital as close contacts of index cases                           18†                  \<16                Moderate
  Domingues 2008     Sept 2004-Nov 2006             Spain          Individuals registered as close contacts of patients                            117                  0-16                Moderate
  Eisenhut 2009      2007                           UK             Outbreak investigation                                                          199                  7-10                Moderate
  Eriksen 2010       2009                           UK             Outbreak investigation---nursery                                                126                  0-9                 High
  Ewer 2003          2001                           UK             School outbreak study                                                           535                  11-15               Moderate
  Hill 2006          June 2002-September 2004       Gambia         Child contacts of patient with sputum smear positive tuberculosis               643†                 0-14                Low
  Okada 2008         2005                           Cambodia       Young children living with pulmonary TB patients                                195†                 0-5                 Moderate
  Rutherford 2012    NS                             Indonesia      Exposed to household and neighbourhood index cases                              330                  9 months-9          Low
  Soysal 2005        October 2002-April 2003        Turkey         Child household contacts of adults with smear positive pulmonary tuberculosis   979                  0-16                High
  Neira-Munoz 2008   2007                           UK             School bus passengers (driver of bus was index case)                            23                   Median 13           High
  Tsiouris 2006      NS                             South Africa   Household contacts of index cases                                               159†                 5-15                Moderate
  Tsolia 2010        1 Jan 2007-31 December 2008    Greece         Contacts with adult with TB who attended TB clinic                              129†                 \<15                Low

NS=not specified.

\*Newcastle-Ottawa scale rating: high \>66.6%; moderate 33.3-66.6%; low \<33.3%.

†Data received from author.

In 13 of the 14 studies patients in the index cases had smear positive active tuberculosis. In one additional study the index case was a patient with smear negative pulmonary tuberculosis. This was a 9 year old child in whom the duration of exposure of contacts at school was for a long unspecified period of time.[@ref11]

Primary analysis
----------------

Our primary analysis with 14 studies and 3855 participants estimated an overall risk ratio of 0.81 (95% confidence interval 0.71 to 0.92, random effects estimate, fig 2)[](#fig2){ref-type="fig"}, indicating 19% protective efficacy against tuberculosis infection among vaccinated children after exposure compared with unvaccinated children. We noted moderate heterogeneity (I^2^=40 %, P\<0.06) between the studies**.** All studies included non-immunocompromised populations, with low probability that specific cut off values are required. The observed protection was similar for the two types of assay: ELISpot (risk ratio 0.83, 95% confidence interval 0.68 to 1.02; four studies) and QuantiFERON (0.78, 0.64 to 0.96; 10 studies) (fig 3).[](#fig3){ref-type="fig"}

![**Fig 2** Protection against *Mycobacterium tuberculosis* infection (TB) as determined by interferon γ release assay (QuantiFERON) in children vaccinated with BCG. D+L=DerSimonian and Laird method; M-H=Mantel-Haenszel method. One test was used per paper and in cases where both ELISpot and QuantiFERON data were available data from QuantiFERON testing were used](roya016946.f2_default){#fig2}

![**Fig 3** Protection against *Mycobacterium tuberculosis* infection (TB) as determined by interferon γ release assay (ELISpot *v* QuantiFERON) in children vaccinated with BCG. D+L=DerSimonian and Laird; M-H=Mantel-Haenszel](roya016946.f3_default){#fig3}

Eight of the 10 Quantiferon studies used Quantiferon In Tube Gold, which includes a further antigen (TB7.7). Further stratification by ELISpot, Quantiferon, and Quantiferon In Tube showed no evidence of inconsistency (data not shown). In eight studies, the cut off for positive assay result was 0.35 IU/mL or they reported using the manufacturer's; one used a cut off of 10 IU/mL[@ref29] and one provided no information---omission of this study does not alter the conclusion.

Subgroup analysis: variables affecting protection against infection
-------------------------------------------------------------------

Figure 4 shows a summary of the subgroup analysis by study characteristics.[](#fig4){ref-type="fig"} Within subgroups for latitude there was moderate heterogeneity; and we found greater protection at higher latitudes, although the difference in protection by latitude was not significant in meta-regression (P=0.56, fig 4).[](#fig4){ref-type="fig"} Studies conducted above 40° latitude showed a protective efficacy of BCG vaccination of 26% (risk ratio 0.74, 95% confidence interval 0.60 to 0.91), while studies conducted at lower latitudes of 20-40° (0.88, 0.54 to 1.45) and 20-0° (0.87, 0.72 to 1.04) (fig A, appendix 1) showed no evidence of a protective effect.

![**Fig 4** Subgroup analyses of protection in children by BCG vaccination against *Mycobacterium tuberculosis* infection (TB) in children vaccinated with BCG, as determined by type of interferon γ release assay, latitude, study quality, and age at vaccination policy comparing areas with (A) and without (B) policy to vaccinate infants at birth; and separate analysis of protection against active disease and against progression from infection to disease in subset of studies (DerSimonian and Laird method)](roya016946.f4_default){#fig4}

Subgroup analysis comparing areas according to recommended age of BCG vaccination (fig B, appendix 1) showed no evidence for a difference in efficacy according to vaccination policy: where the policy was not to vaccinate at birth, protection by BCG against *M tuberculosis* infection was effective (risk ratio 0.72, 95% confidence interval 0.56 to 0.93); and in other areas it was not as effective (0.85, 0.73 to 0.98), with meta-regression giving a P value of 0.27. It was difficult to distinguish between effects of vaccination policy and region.

Exposure to tuberculosis
------------------------

About half (48%) of the children (n=1862, five studies[@ref11] [@ref12] [@ref13] [@ref20] [@ref21]) included were exposed to a single well defined source simultaneously or it was known that there was no difference in exposure.[@ref13] A subgroup analysis of these studies found a higher vaccine efficacy of 28% (risk ratio of 0.73, 95% confidence interval 0.52 to 1.00).

Study quality
-------------

Based on a modified Newcastle-Ottawa scale, we considered three studies to be of high quality, eight of moderate quality, and three of low quality (table[](#tbl1){ref-type="table"} and see appendix 2 for details). Five articles provided information on degree of exposure to infectious cases.[@ref11] [@ref12] [@ref13] [@ref27] [@ref29] Three articles reported that BCG vaccination was given at birth,[@ref13] [@ref26] [@ref27] while the remaining articles did not provide time of vaccination. Two of the articles provided precise information on the timing of interferon γ release assay relative to presumed exposure to an infectious case.[@ref12] [@ref27] Three of the 14 studies included stated that the association between BCG vaccination and a negative assay result was primary or secondary outcome.[@ref11] [@ref12] [@ref13] The study question in Soysal and colleagues was whether BCG vaccination affects the risk of infection in children exposed to tuberculosis.[@ref13] The study of Eisenhut and colleagues was carried out during a school outbreak[@ref11] and the study by Eriksen and colleagues during a nursery outbreak[@ref12]; in both the primary aim was to assess whether BCG vaccination had a protective effect against *M tuberculosis* infection. In two of the articles included the investigators were blinded.[@ref13] [@ref22] In one study, clinical diagnosis of tuberculosis was made without the assay results, and the researchers in the laboratory did not see the clinical data before the tests were carried out.[@ref22] In the second study, people who performed and read the assays were blind to all personal identifiers and results of tuberculin skin tests.[@ref13] Most studies (n=10) were able to show adequate follow-up of exposed children until the interferon γ release assays, with few or no children lost to follow-up between presumed exposure to an infectious case and application of the assay.

We compared studies with a quality rating of 3-4 with those with a rating of ≥5 (fig C, appendix 1). Studies with a rating of ≥5 showed protection (risk ratio 0.68, 95% confidence interval 0.55 to 0.84) and those with a rating of 3 or 4 didn't (0.88, 0.77 to 1.01); (P value for difference 0.06; fig 4)[](#fig4){ref-type="fig"}. This explained 16.4% of heterogeneity between studies (residual heterogeneity I^2^=24%)

Publication bias assessment
---------------------------

The funnel plot in figure 5[](#fig5){ref-type="fig"} showed no evidence of publication bias, and the Harbord test gave a P value of 0.69).[@ref19] One study was dropped from this analysis because of a number of cells in the table with zero observations.[@ref21]

![**Fig 5** Funnel plot (with pseudo confidence intervals) of studies investigating association between BCG vaccination and result of interferon γ release assay](roya016946.f5_default){#fig5}

Secondary analysis---protection against infection *v* protection against disease
--------------------------------------------------------------------------------

We conducted an analysis of six studies that reported the number of people who progressed to active tuberculosis disease during screening.[@ref11] [@ref12] [@ref13] [@ref23] [@ref27] [@ref29] This additional information allowed us to estimate the protective effect of BCG immunisation against infection; the overall protective effect against active tuberculosis; and the protective effect against progression from *M tuberculosis* infection to active disease (fig 6)[](#fig6){ref-type="fig"}. Interferon γ release assay status was not considered (whether performed or not) when we calculated the number of those who developed active tuberculosis within the population. In these six studies, the protection against infection (in all children, irrespective of whether they went on to develop disease) was 27% (risk ratio 0.73, 95 % confidence interval 0.61 to 0.87; fig 7[](#fig7){ref-type="fig"}) and protection against active tuberculosis was 71% (0.29, 0.15 to 0.58). Protection by BCG against progression from infection to active disease, calculated by using infected individuals, was 58% (0.42, 0.23 to 0.77; fig 6 and fig 7).[](#fig6){ref-type="fig"} [](#fig7){ref-type="fig"}

![**Fig 6** Schematic representation of protective effect of BCG immunisation against *Mycobacterium tuberculosis* infection, active tuberculosis, and progression to active tuberculosis from infection during screening from subset of six articles with data on active tuberculosis (vaccine efficacy (VE) and 95% confidence intervals)](roya016946.f6_default){#fig6}

![**Fig 7** Types of protection against *Mycobacterium tuberculosis* (TB) in children vaccinated with BCG: protection against infection (irrespective of whether they went on to develop active TB); overall protection against active TB; protection against progression from infection to active TB during screening. D+L=DerSimonian and Laird method; M-H=Mantel-Haenszel method](roya016946.f7_default){#fig7}

Discussion
==========

Principal findings
------------------

This systematic review shows that BCG vaccination can protect against *M tuberculosis* infection and consolidates the results from recent studies showing evidence of protection against infection.[@ref11] [@ref12] [@ref13] [@ref29] Our results support a paradigm shift in the understanding of how antimycobacterial vaccines (new and old) can work, from the view that BCG protects against disease but not against infection to one that it protects against infection itself.[@ref31]

A recent double blind randomised placebo controlled phase 2b trial of a BCG prime-MVA85A boost vaccination in infants showed no evidence of additional protection, over and above that of BCG against tuberculosis disease infection.[@ref32] This is despite MVA85A inducing a significantly higher Ag85-specific CD4 positive T cell expression of interferon γ, TNFα, and interleukin 2 compared with placebo. One possible explanation for this lack of increased efficacy might be that BCG conferred protection against *M tuberculosis* infection was sufficiently high such that an additional immunisation with MVA85A was unable to confer additional protection.

The observed protection against *M tuberculosis* infection was independent of the assay method used for measurement. There was no evidence of protection against infection less than 40° latitude away from the equator, although the number of studies was small and the difference was not significant. If this finding is confirmed, then the effect of latitude would be consistent with the variation in protection by BCG against pulmonary disease.[@ref8] In this case, the mechanism here could be the same: that the higher prevalence of non-tuberculous mycobacterial infection close to the equator decreases the measured protection with BCG. The limited number of studies reviewed from locations closer to the equator, however, means that firm conclusions must wait until new studies find similar results.

High quality studies also showed protection by BCG vaccination against infection, while lower quality studies did not suggest that study design factors in smaller low quality studies led to the inability to detect a protective effect. This has been observed in systematic reviews of trials of BCG vaccination against tuberculosis.[@ref8]

We found evidence of progression to active tuberculosis as identified at point of screening of index cases. Our interpretation of progression at the time of screening potentially includes both early and late progressors because of uncertainty of the timing of progression to active disease. Publication of an analysis of follow-up data from a study used in this meta-analysis[@ref13] recently reported protective efficacy of the vaccine of 67% for protection against progression from infection to active disease.[@ref33] Similar longitudinal cohorts and randomised control trials will provide a better understanding of the protective efficacy of BCG vaccination.

Limitations and strengths
-------------------------

Our results should be treated with caution for several reasons. Data were not always complete, and we could not control for, or explore interaction with, all variables. For instance, it was assumed there was no prior infection before the documented exposure to active disease or outbreak. Such exposure, however, should affect vaccinated and unvaccinated children equally. Vaccinated children are unlikely to be different from unvaccinated children in other ways that could contribute to protection from infection. We attempted to lower the probability of prior exposure by restricting the analysis to children aged under 16.

We tried to minimise bias from differences in exposure in the two groups by limiting the review to studies among contacts---that is, to outbreaks among contacts of infectious cases or known household exposure where exposure is likely to be similar in vaccinated and unvaccinated children. It is important, however, to consider the possibility that studies included in this review had vaccine recipients who were less likely to be exposed to infection before the outbreak. Exposure can differ because of variable duration of infectiousness of the index patient and the amount of effective contact.

Reduced infection rates in children immunised with BCG could also be caused by the fact that parents who are generally more aware of infection control measures are from higher educated families with lower exposure to *M tuberculosis* infection and have their children more comprehensively immunised, which includes BCG immunisation. A further potential source of bias relates to the greater likelihood that private paediatricians who care for children from medium and high socioeconomic levels might recommend against BCG vaccination if they consider these children to be at a lower risk of infection. We included various observational studies from settings with different socioeconomic backgrounds, potentially neutralising such bias.

We also acknowledge that further quantification of degree of exposure to tuberculosis cases, including proximity to the index case and the number of cases in close contact, was not possible in our study because the primary studies were not designed to compare exposure in children who were and were not immunised with BCG.

Investigation of the effect of age at vaccination at an individual level and of time from vaccination to exposure to an infectious case would be of particular interest. The use of interferon γ release assays as an indicator of infection is still subject to some debate, although this is currently the best marker for infection and certainly discriminates well between infection with *M tuberculosis* and previous BCG vaccination.

There are suggestions that different strains of BCG can induce a broad range of immunological response, which in turn brings about a change in the level of protection. A recent meta-analysis of trials, including 18 studies reporting on protection against pulmonary and six reporting on protection against miliary or meningeal tuberculosis, showed no evidence that efficacy of BCG was associated with vaccination strains.[@ref8] These results are consistent with results from the UKMRC trials, which found equivalent protection by the Copenhagen strain of BCG and an *M microti* derived vaccine.[@ref6] Only three[@ref11] [@ref13] [@ref27] of the 14 studies included in our review provided information on the BCG vaccine strains used, so we also used the UK studies[@ref11] [@ref12] [@ref13] [@ref20] [@ref21] [@ref27] from which we had information on the strains of BCG used in British school children and found no evidence of bias by vaccine strain (data not shown).

We limited subgroup analyses to investigate heterogeneity because of the potential for spurious findings. Where assessed, the main differences in the subgroup analyses were for rating on the Newcastle-Ottawa scale, the P value for which was similar under the permutation test recommended by Higgins and Thompson.[@ref17] Similarly, the small number of studies limited the power to explore whether the variation in protection by BCG against tuberculosis is mostly through variation in protection against infection. The primary aim of most (75%) studies reviewed was not to investigate BCG protection against infection. This, taken in combination with our symmetrical funnel plot, suggests that our findings are unlikely to be caused by publication or reporting bias.

Implications and conclusions
----------------------------

The effect of BCG vaccination, and its policy implications, would be different for countries with high versus low incidence of tuberculosis especially in terms of the cost effectiveness of policies. Countries with a policy of vaccination at birth tend to be those countries with a higher incidence of tuberculosis (cut off \>20/100 000 according to European Centre for Disease Prevention (ECDC)) than those countries without such vaccination policy (\<20/100 000). Given the incomplete control of tuberculosis, especially in high burden countries, optimisation of use of BCG is sensible. Our analysis supports vaccinating children as soon as possible after birth to prevent infection and disease.

Our results provide evidence that BCG protects against tuberculosis infection from multiple epidemiologically different settings and independent of the type of interferon γ release assay used to detect infection. Future trials of candidate vaccines need to investigate the efficacy of the new vaccine against tuberculosis infection and early progression and late progression to active disease. In addition, transparent reporting from outbreak and contact studies of individual ages and time of vaccination and exposure to tuberculosis of participants should allow future meta-analysis to investigate protection against infection. Our results also suggest that models of BCG impact should be revised to include an effect against infection and consequently latent *M tuberculosis* infection and reactivation as without this the effect of BCG would be underestimated.

### What is already known on this topic

1.  Numerous efficacy trials indicate that BCG has 60-80% protective efficacy against severe forms of tuberculosis in children, particularly meningitis; its efficacy when given to adults against pulmonary diseases varies geographically probably because of previous infection when BCG is given

2.  The recently developed T cell based interferon γ release assays can detect *M tuberculosis* infection and discriminate this from previous BCG vaccination and most non-tuberculous mycobacterial infections, allowing investigation of whether BCG protects against *M tuberculosis* infection

### What this study adds

1.  In addition to protection against tuberculosis disease, BCG protects against tuberculosis infection

2.  A protective effect against tuberculosis infection was observed from multiple epidemiologically different settings and independent of the type of interferon γ release assay used to detect infection
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